Virax Biolabs Group LtdVRAX
What Virax Biolabs Group Ltd does.
Virax Biolabs Group Limited is a holding company incorporated as an exempted company under the laws of the Cayman Islands. As a holding company with no material operations of its own, we conduct substantially all of our operations through subsidiaries in the United Kingdom, the United States and China. We commenced operations in 2013.
We are a biotechnology company focused on immune response detection, T cell immune profiling and the development of in vitro diagnostic technologies for viral and immune-mediated diseases. Our current strategic focus is on post-acute infection syndromes (“PAIS”) and related areas of chronic immune dysfunction. Our principal development activities are centred on T cell-based immune profiling and in vitro diagnostics.
(ii) ImmuneSelect , our research-use-only (“RUO”), portfolio of peptide pools, ELISpot plates and related immune reagents.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $123,820 | $0 | $8,561 | $156,419 | $6,331 |
| Net income | — | -$650,984 | -$1.7M | -$5.5M | -$6.7M | -$6.1M |
| Free cash flow | — | — | — | — | -$7.2M | -$5.2M |
More on VRAX.
- Virax Biolabs Group Ltd summary
- Virax Biolabs Group Ltd financial statements
- Virax Biolabs Group Ltd key metrics
- Virax Biolabs Group Ltd health scores and style box
- Virax Biolabs Group Ltd earnings
- Virax Biolabs Group Ltd dividends
- Virax Biolabs Group Ltd valuation
- Virax Biolabs Group Ltd ownership and insiders
- Virax Biolabs Group Ltd peers
Figures from Virax Biolabs Group Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.